iRhythm Technology shares are trading lower after the company received an FDA warning letter related to its Cypress, California facility. The letter alleged non-conformities to regulations for medical devices related to the company's Zio AT system.
Portfolio Pulse from Benzinga Newsdesk
iRhythm Technology received an FDA warning letter regarding non-conformities to regulations for medical devices at its Cypress, California facility, specifically related to the Zio AT system.
May 31, 2023 | 2:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
iRhythm Technology's stock is trading lower after receiving an FDA warning letter about non-conformities at its Cypress facility, affecting the Zio AT system.
The FDA warning letter directly impacts iRhythm Technology's operations at its Cypress facility, specifically the Zio AT system. This negative news is likely to cause a short-term decline in the company's stock price as investors react to the regulatory issue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100